GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Gross Profit

Abionyx Pharma (XPAR:ABNX) Gross Profit : €0.62 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Gross Profit?

Abionyx Pharma's gross profit for the six months ended in Dec. 2023 was €0.63 Mil. Abionyx Pharma's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was €0.62 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Abionyx Pharma's gross profit for the six months ended in Dec. 2023 was €0.63 Mil. Abionyx Pharma's Revenue for the six months ended in Dec. 2023 was €2.51 Mil. Therefore, Abionyx Pharma's Gross Margin % for the quarter that ended in Dec. 2023 was 25.04%.

Abionyx Pharma had a gross margin of 25.04% for the quarter that ended in Dec. 2023 => Competition eroding margins

During the past 11 years, the highest Gross Margin % of Abionyx Pharma was 38.37%. The lowest was 12.11%. And the median was 13.32%.


Abionyx Pharma Gross Profit Historical Data

The historical data trend for Abionyx Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Gross Profit Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.26 0.64 0.62

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.09 0.54 -0.01 0.63

Competitive Comparison of Abionyx Pharma's Gross Profit

For the Biotechnology subindustry, Abionyx Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Gross Profit falls into.



Abionyx Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Abionyx Pharma's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=4.64 - 4.022
=0.62

Abionyx Pharma's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=2.512 - 1.883
=0.63

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.62 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Abionyx Pharma's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.63 / 2.512
=25.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Abionyx Pharma  (XPAR:ABNX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Abionyx Pharma had a gross margin of 25.04% for the quarter that ended in Dec. 2023 => Competition eroding margins


Abionyx Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Abionyx Pharma (XPAR:ABNX) Business Description

Traded in Other Exchanges
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines